Vector Gene Technology

Vector Gene Technology (VGTC) is a pioneering Chinese biotechnology company founded in 2000, specializing in the development and manufacturing of viral vectors for gene therapy. As one of the first companies in China to establish GMP-compliant facilities for adeno-associated virus (AAV) and adenoviral vectors, VGTC has played a critical role in the country's gene therapy landscape. The company is notably recognized for developing China's first gene therapy for hemophilia B and providing high-quality vector services to academic and clinical researchers. Its technology platform, including the AdMax adenovirus system, supports a pipeline targeting genetic disorders and various cancers. Under the leadership of founder Lixin Jiang, the company's expertise has transitioned into Next Generation Gene Therapeutics (NGGT), which currently advances clinical-stage programs for ophthalmic and metabolic diseases.